Repare Therapeutics Inc
RPTX1.780USD
-0.060-3.26%
收盘 11/04, 16:00（美东）报价延迟15分钟
76.47M总市值
亏损市盈率 TTM
关于 Repare Therapeutics Inc 公司
Repare Therapeutics Inc. 是一家临床阶段精准肿瘤学公司，通过其专有的合成致死法来发现和开发新型疗法。该公司利用其全基因组、支持 CRISPR 的 SNIPRx 平台系统地发现和开发高度针对性的癌症疗法，重点是基因组不稳定性，包括 DNA 损伤修复。其产品线包括 lunresertib (RP-6306)，一种处于 1/2 期临床开发的 PKMYT1 抑制剂；camonsertib (RP-3500)，一种潜在的共济失调毛细血管扩张症和 Rad3 相关蛋白激酶 (ATR) 抑制剂，处于 1/2 期临床开发；RP-1664，一种 1 期 PLK4 抑制剂；RP-3467，一种临床前聚合酶 θ 腺苷三磷酸酶 (ATPase) 抑制剂项目，以及其他未公开的临床前项目。 RP-3500 是一种强效、选择性口服小分子 ATR 抑制剂，目前正处于临床开发阶段，用于治疗具有特定 DNA 损伤修复相关基因组改变的实体肿瘤。
Repare Therapeutics Inc简介
公司代码RPTX
公司名称Repare Therapeutics Inc
上市日期Jun 19, 2020
CEOMr. Steve Forte
员工数量129
证券类型Ordinary Share
年结日Jun 19
公司地址7210 Frederick-Banting, Suite 100
城市ST-LAURENT
上市交易所NASDAQ Global Select Consolidated
国家Canada
邮编H4S 2A1
电话18574127018
网址https://www.reparerx.com/
公司代码RPTX
上市日期Jun 19, 2020
CEOMr. Steve Forte
Repare Therapeutics Inc公司高管
名称
名称/职务
职务
持股
持股变动
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
Dr. Susan M. Molineaux, Ph.D.
Dr. Susan M. Molineaux, Ph.D.
Independent Director
Independent Director
--
--
Dr. Steven H. Stein, M.D.
Dr. Steven H. Stein, M.D.
Independent Director
Independent Director
--
--
Dr. David P. Bonita, M.D.
Dr. David P. Bonita, M.D.
Independent Director
Independent Director
--
--
Dr. Samarth Kulkarni, Ph.D.
Dr. Samarth Kulkarni, Ph.D.
Independent Director
Independent Director
--
--
名称
名称/职务
职务
持股
持股变动
Dr. Michael Zinda, Ph.D.
Dr. Michael Zinda, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
48.78K
-16.35%
Ms. Sandra Alves
Ms. Sandra Alves
Senior Vice President, Chief Accounting Officer
Senior Vice President, Chief Accounting Officer
29.62K
+16.06%
Mr. Steve Forte
Mr. Steve Forte
President, Chief Executive Officer, Chief Financial Officer, Director
President, Chief Executive Officer, Chief Financial Officer, Director
23.28K
+32.63%
Ms. Carol Anne Schafer
Ms. Carol Anne Schafer
Independent Director
Independent Director
8.00K
--
Mr. Thomas Civik
Mr. Thomas Civik
Independent Chairman of the Board
Independent Chairman of the Board
7.50K
--
Ms. Ann D. Rhoads
Ms. Ann D. Rhoads
Independent Director
Independent Director
4.00K
--
收入明细
暂无数据
暂无数据
业务
地区
暂无数据
股东统计
更新时间: 10月28日 周二
更新时间: 10月28日 周二
持股股东
股东类型
持股股东
持股股东
占比
BVF Partners L.P.
24.05%
Blue Owl Capital Holdings LP
8.02%
OrbiMed Advisors, LLC
7.73%
Versant Ventures
6.16%
Redmile Group, LLC
3.69%
其他
50.34%
持股股东
持股股东
占比
BVF Partners L.P.
24.05%
Blue Owl Capital Holdings LP
8.02%
OrbiMed Advisors, LLC
7.73%
Versant Ventures
6.16%
Redmile Group, LLC
3.69%
其他
50.34%
股东类型
持股股东
占比
Hedge Fund
29.96%
Investment Advisor/Hedge Fund
11.21%
Investment Advisor
9.09%
Private Equity
7.82%
Venture Capital
6.26%
Individual Investor
1.41%
Research Firm
0.22%
Family Office
0.09%
其他
33.94%
机构持股
更新时间: 10月1日 周三
更新时间: 10月1日 周三
报告期
机构数
持股数
持股占比
持股变动
2025Q3
151
27.74M
64.57%
-9.61M
2025Q2
171
30.95M
72.17%
-10.10M
2025Q1
185
33.16M
77.30%
-8.74M
2024Q4
193
34.29M
80.67%
-8.93M
2024Q3
196
36.17M
85.09%
-7.71M
2024Q2
200
37.54M
88.44%
-7.90M
2024Q1
203
39.40M
93.34%
-5.92M
2023Q4
206
40.21M
95.29%
-816.82K
2023Q3
207
37.21M
88.27%
-2.03M
2023Q2
203
37.24M
88.48%
-4.72M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
BVF Partners L.P.
10.33M
24.05%
--
--
Jun 30, 2025
Blue Owl Capital Holdings LP
3.44M
8.02%
+71.16K
+2.11%
Jun 30, 2025
OrbiMed Advisors, LLC
3.32M
7.73%
+122.13K
+3.82%
Jun 30, 2025
Versant Ventures
2.65M
6.16%
-321.00K
-10.82%
Jun 30, 2025
Redmile Group, LLC
1.59M
3.69%
-298.21K
-15.83%
Jun 30, 2025
MPM Capital Inc.
1.12M
2.61%
--
--
Jun 30, 2025
Citadel Advisors LLC
937.49K
2.18%
--
--
Jun 30, 2025
MPM BioImpact LLC
819.92K
1.91%
--
--
Jun 30, 2025
Acadian Asset Management LLC
681.18K
1.59%
+40.85K
+6.38%
Jun 30, 2025
Renaissance Technologies LLC
522.86K
1.22%
+224.20K
+75.07%
Jun 30, 2025
查看更多
持股ETF
更新时间: 11月2日 周日
更新时间: 11月2日 周日
机构名称
占比
ARK Genomic Revolution ETF
0%
Avantis US Small Cap Equity ETF
0%
Avantis US Equity ETF
0%
SPDR S&P International Small Cap ETF
0%
ARK Genomic Revolution ETF
占比0%
Avantis US Small Cap Equity ETF
占比0%
Avantis US Equity ETF
占比0%
SPDR S&P International Small Cap ETF
占比0%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据
